Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers

Zymeworks Announces Participation In Upcoming Investor Conferences

Zymeworks Showcases New and Updated Clinical Data for Zanidatamab at ASCO 2023

Zymeworks is pleased to announce, along with our partners Jazz Pharmaceuticals and BeiGene, new and updated data from two ongoing clinical trials evaluating zanidatamab, a HER2-targeted bispecific antibody for the treatment of solid tumors, at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2 to June 6 in Chicago, IL. Results […]
Zymeworks Announces Departure of Neil Klompas, President and Chief Operating Officer

Zymeworks Provides Corporate Update and Reports First Quarter 2023 Financial Results

Zymeworks Announces Participation In Upcoming Investor Conferences

Zymeworks Presents New Data from Multiple Preclinical and Clinical Development Programs at the 2023 American Association for Cancer Research Annual Meeting

Zymeworks To Host First Quarter 2023 Results Conference Call

Zymeworks Announces Appointment of Derek J. Miller to its Board of Directors

Zymeworks Announces Participation In Upcoming Investor Conferences

Zymeworks To Present Updated Data On Multiple Product Candidates At The American Association For Cancer Research (AACR) Annual Meeting

Zymeworks Reports Fourth Quarter and Full Year 2022 Financial Results
